Outset Medical (NASDAQ:OM) CEO Sells $15,088.43 in Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 3,437 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $4.39, for a total transaction of $15,088.43. Following the transaction, the chief executive officer owned 194,597 shares of the company’s stock, valued at $854,280.83. This trade represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Outset Medical Price Performance

Outset Medical stock opened at $4.30 on Friday. Outset Medical, Inc. has a 52 week low of $3.00 and a 52 week high of $16.16. The business has a 50-day simple moving average of $4.57 and a 200 day simple moving average of $4.22. The company has a quick ratio of 4.11, a current ratio of 5.19 and a debt-to-equity ratio of 1.03. The stock has a market cap of $80.83 million, a price-to-earnings ratio of -1.05 and a beta of 1.96.

Outset Medical (NASDAQ:OM) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.08). The business had revenue of $31.64 million during the quarter, compared to analysts’ expectations of $28.97 million. Outset Medical had a negative net margin of 63.06% and a negative return on equity of 61.67%. On average, research analysts forecast that Outset Medical, Inc. will post -3.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on OM. Wall Street Zen raised shares of Outset Medical from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. TD Cowen reissued a “buy” rating on shares of Outset Medical in a research note on Friday, May 8th. Finally, Weiss Ratings raised shares of Outset Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 7th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Outset Medical currently has an average rating of “Hold” and a consensus price target of $10.00.

Institutional Investors Weigh In On Outset Medical

Hedge funds have recently added to or reduced their stakes in the company. BML Capital Management LLC purchased a new stake in Outset Medical in the fourth quarter worth approximately $2,015,000. Renaissance Technologies LLC grew its position in Outset Medical by 391.3% during the first quarter. Renaissance Technologies LLC now owns 222,075 shares of the company’s stock valued at $853,000 after acquiring an additional 176,870 shares during the last quarter. R Squared Ltd purchased a new position in shares of Outset Medical during the first quarter worth approximately $65,000. Aristides Capital LLC purchased a new position in shares of Outset Medical during the fourth quarter worth approximately $177,000. Finally, Sei Investments Co. raised its stake in shares of Outset Medical by 15.5% during the first quarter. Sei Investments Co. now owns 35,366 shares of the company’s stock worth $136,000 after acquiring an additional 4,738 shares in the last quarter.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long?term care facilities and emergency response scenarios.